Revenue Insights: Telix Pharmaceuticals Limited and TG Therapeutics, Inc. Performance Compared

Biotech Revenue Surge: Telix vs. TG Therapeutics

__timestamp	TG Therapeutics, Inc.	Telix Pharmaceuticals Limited
Wednesday, January 1, 2014	152381	28336824
Thursday, January 1, 2015	152381	32319194
Friday, January 1, 2016	152381	29404631
Sunday, January 1, 2017	152381	31769230
Monday, January 1, 2018	152000	20439380
Tuesday, January 1, 2019	152000	24186536
Wednesday, January 1, 2020	152000	4680000
Friday, January 1, 2021	6689000	4898000
Saturday, January 1, 2022	2785000	155984000
Sunday, January 1, 2023	233662000	496659000

Unveiling the hidden dimensions of data

Revenue Growth: A Tale of Two Biotechs

In the competitive landscape of biotechnology, Telix Pharmaceuticals Limited and TG Therapeutics, Inc. have showcased intriguing revenue trajectories over the past decade. From 2014 to 2023, Telix Pharmaceuticals experienced a remarkable surge, with revenue peaking at nearly 500 million in 2023, a staggering increase of over 1,600% from its 2014 figures. In contrast, TG Therapeutics saw a more volatile journey, culminating in a significant revenue spike in 2023, reaching approximately 234 million, a dramatic leap from its consistent figures around 152,000 in earlier years.

This data highlights the dynamic nature of the biotech industry, where strategic innovations and market demands can lead to exponential growth. As these companies continue to evolve, their financial performance offers valuable insights into the sector's future trends.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025